Cyclodextrin-based nanosponges encapsulating camptothecin: Physicochemical characterization, stability and cytotoxicity

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 74, Issue 2, 2010, Pages 193-201

  Swaminathan, Shankar ^a,b   Pastero, Linda ^a   Serpe, Loredana ^a   Trotta, Francesco ^a   Vavia, Pradeep ^b   Aquilano, Dino ^a   Trotta, Michele ^a   Zara, GianPaolo ^a   Cavalli, Roberta ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Cyclodextrin; Camptothecin; Complexation; Crystallinity; Cytotoxicity; Nanosponges; Stability

Indexed keywords

BETA CYCLODEXTRIN; CAMPTOTHECIN; CRYSTALLIN; LACTONE; NANOPARTICLE; NANOSPONGE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HT29; CHEMICAL INTERACTION; COLORECTAL ADENOMA; COMPLEX FORMATION; CONTROLLED STUDY; CROSS LINKING; CRYSTALLOID; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; HEMOLYSIS; HUMAN; HUMAN CELL; HYDROLYSIS; INFRARED SPECTROSCOPY; NANOENCAPSULATION; PARTICLE SIZE; X RAY POWDER DIFFRACTION; ZETA POTENTIAL;

CAMPTOTHECIN; CELL DEATH; CYCLODEXTRINS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; HT29 CELLS; HUMANS; NANOSTRUCTURES; PHYSICOCHEMICAL PHENOMENA;

EID: 75449094412     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2009.11.003     Document Type: Article

References (26)

1. F. Trotta, W. Tumiatti, WO 03/085002, 2003.
2. Trotta F., and Cavalli R. Characterization and application of new hyper-cross-linked cyclodextrins. Compos. Interfaces 16 (2009) 39-48
3. Cavalli R., Trotta F., and Tumiatti W. Cyclodextrin-based nanosponges for drug delivery. J. Incl. Phenom. Macrocycl. Chem. 56 (2006) 209-213
4. Swaminathan S., Vavia P.R., Trotta F., and Torne S. Formulation of betacyclodextrin based nanosponges of itraconazole. J. Incl. Phenom. Macrocycl. Chem. 57 (2007) 89-94
5. P.R. Vavia, S. Swaminattan, F. Trotta, R. Cavalli, Applications of Nanosponges in Drug Delivery XIII International Cyclodextrin Symposium, Turin 14-17, May 2006.
6. S. Swaminathan, Studies on Novel Dosage Forms, M Pharm. Sci. Thesis, University of Mumbai, India, July 2006.
7. Hertzberg R.P., Caranfa M.J., and Hecht S.M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 28 (1989) 4629-4638
8. Dancey J., and Eisenhauer E.A. Current perspectives on camptothecin in cancer treatment. Br. J. Cancer 74 (1996) 327-338
9. Potmesil M., and Pinedo H.M. Camptothecins: New Anticancer Agents (1995), CRC Press, Boca Raton
10. Takimoto C.H., Wright J., and Arbuck S.G. Clinical applications of the camptothecins. Biochim. Biophys. Acta 1400 (1998) 107-119
11. Wall M.E., Wani M.C., Cook C.E., Palmer K.H., McPhail A.T., and Sim G.A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca accuminata. J. Am. Chem. Soc. 88 (1966) 3888-3890
12. Hsiang Y.H., Hertzberg R., Hecht S., and Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260 (1985) 14873-14878
13. Fassberg J., and Stella V.J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. 81 (1992) 676-684
14. Chourpa I., Millot J.M., Sockalingum G.D., Riou J.F., and Manfait M. Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy. Biochim. Biophys. Acta 1379 (1998) 353-366
15. Burke T.G., Mishra A.K., Wani M.C., and Wall M.E. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry 32 (1993) 5352-5364
16. Hatefi A., and Amsden B. Camptothecin delivery methods. Pharm. Res. 19 (2002) 1389-1399
17. Scenderova A., Burke T., and Schwendeman S. Stabilization of 10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles. Pharm. Res. 14 10 (1997) 1406
18. Cortesi R., Esposito E., Maietti A., Menegatti E., and Nastruzzi C. Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion. Int. J. Pharm. 159 (1997) 95-103
19. Kunii R., Onishi H., and Machida Y. Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin. Eur. J. Pharm. Biopharm. 67 (2007) 9-17
20. Davis M.E. Design and development of IT-101, a cyclodextrin containing polymer conjugate of camptothecin. Adv. Drug Deliv. Rev. 61 (2009) 1189-1192
21. Huang Z., Hua S., Yang Y., and Fang J. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol. Sinica 9 (2008) 1094-1102
22. Barrada M., Serreqi A., Dabbarh F., Owusu A., Gupta A., and Lehnert S. A novel non-toxic camtothecin formulation for cancer chemotherapy. Biomaterials 26 (2005) 2115-2120
23. Fang J., Hung C., Hua S., and Hwang T. Acoustically active perfluorocarbon nanoemulsions as drug delivery carriers for camptothecin: drug release and cytotoxicity against cancer cells. Ultrasonics 49 (2009) 39-46
24. Kang J., Kumar V., Yang D., Chowdhury P.R., and Hohl R.J. Cyclodextrin complexation: influence on solubility, stability and cytotoxicity of camptothecin. Eur. J. Pharm. Sci. 15 (2002) 163-170
25. Saetern A., Nguyen N., Bauer-Brandl A., and Brandl M. Effect of hydroxypropyl-β-cyclodextrin-complexation and pH on solubility of camptothecin. Int. J. Pharm. 284 (2004) 61-68
26. Moon C., Kwon Y., Lee W., Park Y., Chang L., and Yang V. A novel polyrotaxane-based intracellular deliery system for camptothecin: in vitro feasibility. J. Biomedical Mat. Res. Part A 84 (2008) 238-246